IMMX vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

IMMX

51.0
AI Score
VS
IMMX Wins

DNA

41.6
AI Score

Investment Advisor Scores

IMMX

51score
Recommendation
HOLD

DNA

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IMMX DNA Winner
Revenue 20.00M 170.16M DNA
Net Income -21.64M -313,000 DNA
Net Margin -108.2% -0.2% DNA
Operating Income -23.26M -315.28M IMMX
ROE -9.5% -0.1% DNA
ROA -9.1% -0.0% DNA
Total Assets 239.11M 1.12B DNA
Cash 225.49M 167.20M IMMX
Current Ratio 25.13 4.92 IMMX
Free Cash Flow -21.62M -178.72M IMMX

Relative Price Performance (Last 90 Days)

IMMX 1M: -30.7% · 3M: -7.4% DNA 1M: +75.7% · 3M: +22.2%

Current Technical Phase

IMMX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 31

RSI (14): 31.4 · Price: $9.68

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 75

RSI (14): 74.6 · Price: $12.35

Fundamentals Snapshot

Metric IMMX DNA
Market Cap — —
Forward P/E -11.4 -4.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -0.5%
Gross Margin — 0.7%
Operating Margin 0.0% -2.8%
EPS -0.88 -5.19
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IMMX is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.